Patents Represented by Attorney David M. Morse

Find this attorney in the Justia Lawyer Directory

  • Process for preparing an antibiotic complex by culturing actinomyces strain ATCC 39417
    Patent number: 4572895
    Abstract: A novel antibiotic complex designated BBM-2478 is produced by fermentation of an actinomycete strain J907-21 (ATCC 39417). The complex may be separated chromatographically into two bioactive components designated BBM-2478A and BBM-2478B. The BBM-2478A component displays both antibacterial and antitumor activity while the BBM-2478B component has antibacterial activity.
    Type: Grant
    Filed: February 19, 1985
    Date of Patent: February 25, 1986
    Assignee: Bristol-Myers Company
    Inventors: Masataka Konishi, Koko Sugawara, Takeo Miyaki, Hiroshi Kawaguchi
  • Process for preparing 4'-deschlororebeccamycin
    Patent number: 4567143
    Abstract: A new antitumor antibiotic designated herein as 4'-deschlororebeccamycin is produced by fermentation of Nocardia aerocolonigenes ATCC 39243. The new compound possesses antibacterial activity and inhibits the growth of tumors in experimental animals.
    Type: Grant
    Filed: March 18, 1985
    Date of Patent: January 28, 1986
    Assignee: Bristol-Myers Company
    Inventor: James A. Matson
  • Antitumor platinum complexes
    Patent number: 4562275
    Abstract: Novel platinum(II) complexes of 1,2-diaminocyclohexane, 1-aminomethylcyclooctylamine and 1,2-diamino-2,4-dimethylpentane are provided. Such complexes are of use in inhibiting the growth of certain mammalian tumors.
    Type: Grant
    Filed: March 23, 1984
    Date of Patent: December 31, 1985
    Assignee: Bristol-Myers Co.
    Inventors: Robert J. Speer, David P. Stewart
  • Process for producing rebeccamycin
    Patent number: 4552842
    Abstract: A novel antitumor agent designated herein as rebeccamycin is produced by fermentation of Nocardia aerocolonigenes (ATCC 39243). Rebeccamycin and its 5'-N-methyl and 5',2",3",6"-tetraacetate derivatives exhibit activity against experimental animal tumor systems.
    Type: Grant
    Filed: April 13, 1984
    Date of Patent: November 12, 1985
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., James A. Bush, William T. Bradner, Terrence W. Doyle
  • Carbapenem antibiotics
    Patent number: 4552696
    Abstract: Disclosed are novel carbapenem derivatives characterized by a 2-substituent of the formula ##STR1## in which A represents cyclopentylene, cyclohexylene or C.sub.2 -C.sub.6 alkylene optionally substituted by one or more C.sub.1 -C.sub.4 alkyl groups and ##STR2## represents a quaternized nitrogen-containing aromatic heterocycle. Such derivatives are useful as potent antibacterial agents. Also disclosed are processes for the preparation of such derivatives and novel intermediates utilized in these processes.
    Type: Grant
    Filed: March 8, 1983
    Date of Patent: November 12, 1985
    Assignee: Bristol-Myers Company
    Inventors: Choung U. Kim, Peter F. Misco, Jr.
  • 3.alpha.,15-Bis(chloroacetoxy)-4.beta .-hydroxy-12,13-epoxytrichothec-9-ene useful as an antitumor agent
    Patent number: 4552971
    Abstract: Novel mono-, di- and triacylated derivatives of scirpentriol are provided for use as antitumor agents. Also provided are methods for the production of such derivatives.
    Type: Grant
    Filed: February 27, 1984
    Date of Patent: November 12, 1985
    Assignee: Bristol-Myers Company
    Inventors: Henry Schmitz, Takushi Kaneko, John M. Essery, Terrence W. Doyle
  • Biologically pure culture of Actinomadura Sp.
    Patent number: 4546084
    Abstract: A biologically pure culture of Actinomadura Sp. Strain H710-49 (ATCC 39144) is provided. The antibiotic designated BBM-1644 may be produced by fermentation of the subject culture.
    Type: Grant
    Filed: April 9, 1984
    Date of Patent: October 8, 1985
    Assignee: Bristol-Myers Company
    Inventors: Masataka Konishi, Fumihide Sakai, Takeo Miyaki, Hiroshi Kawaguchi
  • Carbapenem antibiotics
    Patent number: 4536335
    Abstract: Disclosed are novel carbapenem derivatives characterized by a 2-substituent of the formula ##STR1## in which A represents cyclopentylene, cyclohexylene or C.sub.2 -C.sub.6 alkylene optionally substituted by one or more C.sub.1 -C.sub.4 alkyl groups; R.sup.5 represents either (a) an optionally substituted aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, aryl, araliphatic, heteroaryl, heteroaraliphatic, heterocyclyl or heterocyclyl-aliphatic radical or (b) a divalent phenylene or C.sub.1 -C.sub.4 alkylene group joined to the ##STR2## ring so as to form a bridged polycyclic group; and ##STR3## represents a quaternized nitrogen-containing non-aromatic heterocycle. Such derivatives are useful as potent antibacterial agents.
    Type: Grant
    Filed: June 7, 1983
    Date of Patent: August 20, 1985
    Assignee: Bristol-Myers Company
    Inventors: Choung U. Kim, Peter F. Micso, Jr.
  • Fermentation process for preparation of antibiotic Bu-2517
    Patent number: 4533631
    Abstract: Disclosed is a process for preparation of the water-soluble peptide antibiotic designated Bu-2517 by fermentation of Empedobacter sp. strain G393-B445 (ATCC 31962).
    Type: Grant
    Filed: March 25, 1983
    Date of Patent: August 6, 1985
    Assignee: Bristol-Myers Company
    Inventors: Hiroshi Kawaguchi, Masataka Konishi, Koko Sugawara, Koji Tomita
  • 4'-Deschlororebeccamycin pharmaceutical composition and method of use
    Patent number: 4524145
    Abstract: A new antitumor antibiotic designated herein as 4'-deschlororebeccamycin is produced by fermentation of Nocardia aerocolonigenes ATCC 39243. The new compound possesses antibacterial activity and inhibits the growth of tumors in experimental animals.
    Type: Grant
    Filed: September 4, 1984
    Date of Patent: June 18, 1985
    Assignee: Bristol-Myers Company
    Inventor: James A. Matson
  • Production of cephalosporin C
    Patent number: 4520101
    Abstract: Production of undesired desacetylcephalosporin C during fermentation of cephalosporin C-producing microorganisms is substantially reduced by addition of certain phosphorous compounds to the culture medium.
    Type: Grant
    Filed: March 7, 1983
    Date of Patent: May 28, 1985
    Assignee: Bristol-Myers Company
    Inventors: David A. Lowe, Guna Romancik, Leonardo M. Cappelletti, Richard P. Elander
  • BBM-2478 Antibiotic complex
    Patent number: 4518589
    Abstract: A novel antibiotic complex designated BBM-2478 is produced by fermentation of an actinomycete strain J907-21 (ATCC 39417). The complex may be separated chromatographically into two bioactive components designated BBM-2478A and BBM-2478B. The BBM-2478A component displays both antibacterial and antitumor activity while the BBM-2478B component has antibacterial activity.
    Type: Grant
    Filed: October 3, 1983
    Date of Patent: May 21, 1985
    Assignee: Bristol-Myers Company
    Inventors: Masataka Konishi, Koko Sugawara, Takeo Miyaki, Hiroshi Kawaguchi
  • Antitumor antibiotics BBM-2040A and BBM-2040B
    Patent number: 4508647
    Abstract: A novel antitumor antibiotic designated herein as BBM-2040 is produced by fermentation of Streptomyces sp. strain J576-99 (ATCC 39143). BBM-2040, which may be recovered from the fermentation broth in either a desmethanol (BBM-2040B) or methanol-adduct (BBM-2040A) form, inhibits gram positive and acid-fast bacteria and inhibits the growth of tumors such as P388 leukemia in mice.
    Type: Grant
    Filed: May 10, 1984
    Date of Patent: April 2, 1985
    Assignee: Bristol-Myers Company
    Inventors: Masami Hatori, Hiroaki Ohkuma, Masataka Konishi, Takeo Miyaki, Hiroshi Kawaguchi
  • Cephadroxil monohydrate
    Patent number: 4504657
    Abstract: A novel crystalline monohydrate of 7-[D-.alpha.-amino-.alpha.-(p-hydroxyphenyl)acetamido]-3-methyl-3-cephem-4 -carboxylic acid is prepared and found to be a stable useful form of the cephalosporin antibiotic especially advantageous for pharmaceutical formulations.
    Type: Grant
    Filed: March 16, 1982
    Date of Patent: March 12, 1985
    Assignee: Bristol-Myers Company
    Inventors: Daniel Bouzard, Abraham Weber, Jacques Stemer
  • Rebeccamycin and process for its preparation
    Patent number: 4487925
    Abstract: A novel antitumor agent designated herein as rebeccamycin is produced by fermentation of Nocardia aerocolonigenes (ATCC 39243). Rebeccamycin and its 5'-N-methyl and 5',2",3",6"-tetraacetate derivatives exhibit activity against experimental animal tumor systems.
    Type: Grant
    Filed: January 28, 1983
    Date of Patent: December 11, 1984
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., James A. Bush, William T. Bradner, Terrence W. Doyle
  • Antibiotic BMG162-aF2, a process for production thereof, and antitumor drug containing said antibiotic as active ingredient
    Patent number: 4474880
    Abstract: A new antibiotic BMG162-aF2 having the formula ##STR1## can be obtained by cultivating a BMG162-aF2-producing strain belonging to the genus Bacillus in a culture medium to produce and accumulate the said BMG162-aF2 and then recovering it from the culture medium. The antibiotic BMG162-aF2 thus obtained or a pharmaceutically acceptable salt thereof can be used for the treatment of a transplanted tumor in warmblooded animals.
    Type: Grant
    Filed: August 20, 1982
    Date of Patent: October 2, 1984
    Assignee: Zaidan Hojin Biseibutsu Kagaku Kenyku Kai
    Inventors: Hamao Umezawa, Tomio Takeuchi, Hiroshi Naganawa, Hironobu Iinuma, Setsuko Kunimoto
  • Antitumor antibiotics produced by new streptomyces
    Patent number: 4464467
    Abstract: A novel antitumor antibiotic designated herein as BBM-2040 is produced by fermentation of Streptomyces sp. strain J576-99 (ATCC 39143). BBM-2040, which may be recovered from the fermentation broth in either a desmethanol (BBM-2040B) or methanol-adduct (BBM-2040A) form, inhibits gram-positive and acid-fast bacteria and inhibits the growth of tumors such as P388 leukemia in mice.
    Type: Grant
    Filed: July 26, 1982
    Date of Patent: August 7, 1984
    Assignee: Bristol-Myers Company
    Inventors: Masami Hatori, Hiroaki Ohkuma, Masataka Konishi, Takeo Miyaki, Hiroshi Kawaguchi
  • 4-Acylthioazetidinone intermediates for antibacterial agents
    Patent number: 4461727
    Abstract: This invention relates to 2-substituted and 2,6-disubstituted penem compounds of the formula ##STR1## wherein Y is hydrogen, halo or certain organic radicals and X represents certain hetero-interrupted substituted alkyl radicals. Also included in the invention are pharmaceutically acceptable salts of the above compounds and derivatives of the above compounds in which the carboxyl group at the 3-position is protected as by an easily removable ester protecting group. The compounds of the present invention are potent antibacterial agents or are of use as intermediates in the preparation of such agents.
    Type: Grant
    Filed: September 10, 1982
    Date of Patent: July 24, 1984
    Assignee: Bristol-Myers Company
    Inventors: Marcel Menard, Alain Martel
  • Antitumor agents albacarcins V and M
    Patent number: 4461831
    Abstract: Novel antitumor antibiotics designated herein as albacarcins M and V are produced by fermentation of Streptomyces albaduncas strain C-38291 (ATCC 39151). The new antibiotics possess antibacterial activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.
    Type: Grant
    Filed: August 16, 1982
    Date of Patent: July 24, 1984
    Assignee: Bristol-Myers Company
    Inventors: James A. Matson, Robert W. Myllymaki, Terrence W. Doyle, James A. Bush
  • Anti-ulcer agents
    Patent number: 4457932
    Abstract: Disclosed is a method of using certain substituted 3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one compounds, previously known as having antiallergy activity, for the treatment of peptic ulcer disease and other gastrointestinal diseases characterized by inflammation and necrosis.
    Type: Grant
    Filed: July 22, 1983
    Date of Patent: July 3, 1984
    Assignee: Bristol-Myers Company
    Inventors: Peter F. Juby, Thomas W. Hudyma, Douglas G. Colton